The Influence of Neurodevelopmental Treatment on Transforming Growth Factor-β1 Levels and Neurological Remodeling in Children With Cerebral Palsy

Abstract

Neurodevelopmental treatment is an advanced therapeutic approach for the neural rehabilitation of children with cerebral palsy. Cerebral palsy represents a spectrum of neurological disorders primarily affecting gross motor function. The authors investigated the effects of neurodevelopmental treatment on serum levels of transforming growth factor-β1 (TGF-β1), a neuroprotective cytokine, and improvements to motor skills. Serum TGF-β1 levels and total score of the Gross Motor Function Measure–88 (GMFM-88) were significantly higher in children with cerebral palsy who underwent neurodevelopmental treatment compared to untreated patients (P < .01). Furthermore, the improved GMFM-88 total scores after neurodevelopmental treatment were significantly higher in children under the age of 3 with cerebral palsy than in older patients (P < .01). The authors demonstrate that the integration of TGF-β1 levels and GMFM-88 total score could be used to assess the efficacy of neurodevelopmental treatment. Moreover, the findings provide further scientific support for the early intervention and neurological rehabilitation of young children with cerebral palsy.

Keywords

cerebral palsy remodeling neurodevelopmental treatment TGF-β1 Gross Motor Function Measure

Get full access to this article

View all access options for this article.

References

Rosenbaum

Paneth

Leviton

. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8–14.

Scherzer

Tscharnuter

. Early Diagnosis and Therapy in Cerebral Palsy: A Primer on Infant Development Problems. 2nd ed. New York, NY: Marcel Dekker; 1990.

Ottenbacher

Biocca

DeCremer

. Quantitative analysis of the effectiveness of pediatric therapy. Emphasis on the neurodevelopmental treatment approach. Phys Ther. 1986;66:1095–1101.

Barry

. Physical therapy interventions for patients with movement disorders due to cerebral palsy. J Child Neurol. 1996;11:51–60.

Russell

Rosenbaum

Cadman

. The Gross Motor Function Measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol. 1989;31:341–352.

Davison

McCaffrey

Porter

. Improved nerve regeneration neutralization of transforming growth factor-beta1. Laryngoscope. 1999;109:631–635.

Gomes

Sousa Vde

Romao

. Emerging roles for TGF-beta1 in nervous system development. Int J Dev Neurosci. 2005;23:413–424.

Morris

Bartlett

. Gross Motor Function Classification System: impact and utility. Dev Med Child Neurol. 2004;46:60–65.

Martin

Murray

Peter

. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005;47:571–576.

10.

Cramer

Sur

Dobkin

. Harnessing neuroplasticity for clinical applications. Brain. 2011;134:1591–1609.

11.

Law

Russell

Pollock

. A comparison of intensive neurodevelopmental therapy plus casting and a regular occupational therapy program for children with cerebral palsy. Dev Med Child Neurol. 1997;39:664–670.

12.

Salokorpi

Rautio

Kajantie

. Is early occupational therapy in extremely preterm infants of benefit in the long run? Pediatr Rehabil. 2002;5:91–98.

13.

Klimont

. Principles of Bobath neuro-developmental therapy in cerebral palsy. Ortop Traumatol Rehabil. 2001;3:527–530.

14.

Boche

Cunningham

Gauldie

. Transforming growth mediated neuroprotection against excitotoxic injury in vivo. J Cereb Flow Metab. 2003;23:1174–1182.

15.

Zhong

Sarafian

Kane

. Bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Natl Acad Sci USA. 1993;90:4533–4537.

16.

Kastin

Akerstrom

Pan

. Circulating TGF-β1 does not cross the intact blood-brain barrier. J Mol Neurosci. 2003;21:43–48.

17.

Stolp

Dziegielewska

. Review: role of developmental inflammation and blood–brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol Appl Neurobiol. 2009;35:132–146.

18.

Russell

Rosenbaum

Avery

. Gross Motor Function Measure (GMFM-66& GMFM-88) User’s Manual. London, UK: Mac Keith Press; 2002.

19.

Nordmark

Hagglund

Jarnlo

. Reliability of the Gross Motor Function Measure in cerebral palsy. Scand J Rehab Med. 1997;29:25–28.

20.

Sinno

Charafeddine

Mikati

. Enhancing Childhood Development in Children with Cerebral Palsy and Other Disorders. New York, NY: Springer; 2012.

21.

Tao

Wen

Yao

. The influence of erythropoietin and proinflammatory cytokines in the development of cerebral palsy. Vascular Dis Prev. 2008;5:29–32.

22.

Tao

Wen

Zhang

. The signal transduction mediated by erythropoietin and proinflammatory cytokines in the JAK/STAT pathway in the children with cerebral palsy. Brain Dev. 2009;31:200–207.

23.

Bruce-Keller

Mattson

. Mechanisms of Neuroprotective Cytokines. New York, NY: Humana Press; 1999.